EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting rare tumors: new focus for clinical research in China

Shuhang Wang, Yale Jiang iD, Huilei Miao, Yuan Fang iD, Ning Jiang iD, Yue Yu, Peiwen Ma, Qiyu Tang, Dandan Cui, Hong Fang, Huiyao Huang, Qi Fan und 7 weitere

EMBO Molecular Medicine · 11.01.2023 · 15 (1)

DOI: 10.15252/emmm.202216415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, online erschienen am 28.11.2022. Verfasst von Shuhang Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bejing Municipal Health Commission, Bejing Demonstration Research Ward, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule‐guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansChinaClinical Trials, Phase II as Topic

Autor:innen und Institutionen

  • Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Yale Jiang, Yuan Fang, Ning Jiang, Ning Li

Förderung

  • Bejing Municipal Health Commission, Bejing Demonstration Research Ward
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences

Zitieren

APA

Wang, S., Jiang, Y., Miao, H., Fang, Y., Jiang, N., Yu, Y., Ma, P., Tang, Q., Cui, D., Fang, H., Huang, H., Fan, Q., Sun, C., Yu, A., Miao, S., Du, J., Zhu, J., Wang, Y., & Li, N. (2023). Targeting rare tumors: new focus for clinical research in China. EMBO Molecular Medicine, 15(1). https://doi.org/10.15252/emmm.202216415

Vancouver

Wang S, Jiang Y, Miao H, Fang Y, Jiang N, Yu Y, et al. Targeting rare tumors: new focus for clinical research in China. EMBO Molecular Medicine. 2023;15(1). doi:10.15252/emmm.202216415

BibTeX
@article{Wang2023,
  author = {Wang, Shuhang and Jiang, Yale and Miao, Huilei and Fang, Yuan and Jiang, Ning and Yu, Yue and Ma, Peiwen and Tang, Qiyu and Cui, Dandan and Fang, Hong and Huang, Huiyao and Fan, Qi and Sun, Chao and Yu, Anqi and Miao, Shuangman and Du, Jingting and Zhu, Jingxiao and Wang, Yuning and Li, Ning},
  title = {Targeting rare tumors: new focus for clinical research in China},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  volume = {15},
  number = {1},
  doi = {10.15252/emmm.202216415}
}
Kostenlos starten →